Outside trials, psilocybin's real-world depression response rate ran lower

Clinical trials of psilocybin for depression have generally been conducted under tightly controlled conditions with careful screening and structured protocols. What happens when the drug is used outside that trial setting, in routine psychiatric care, has been almost entirely unknown — a gap a study published this month in The Lancet Regional Health – Europe begins to fill, using Switzerland's distinctive legal framework that permits limited medical use of psilocybin for treatment-resistant depression [s1].

The design

Researchers conducted a retrospective analysis of medical records from 19 patients with treatment-resistant depression treated with psilocybin (doses ranging from 20 to 35 mg) across one to four dosing sessions at the Psychiatric University Hospital Zurich [s1]. Depression severity was assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS) and the Beck Depression Inventory II (BDI), comparing baseline to interim and post-treatment scores [s1].

What it found

MADRS scores fell from a baseline mean of 30.78 to a post-treatment mean of 19.89, a large effect size (Hedges' g = 1.37, 95% CI 0.90–1.84) [s1]. BDI scores fell from a mean of 32.33 to 23.28, a medium-to-large effect (Hedges' g = 0.77, 95% CI 0.46–1.09) [s1]. Response and remission rates were 33.3% and 22.2% on the MADRS, and 27.8% and 27.8% on the BDI [s1]. No serious adverse events were documented [s1].

Why "below trial-reported figures" is the honest headline here

The study's own authors are direct about this: response and remission rates in this real-world sample ran below what's typically reported in controlled psilocybin depression trials [s1]. That's a meaningful and somewhat expected finding rather than a disappointing one — real-world clinical populations tend to be more heterogeneous, less rigorously screened, and treated with more variable protocols than trial participants, and this study explicitly notes its patients received "concomitant psychopharmacology" (other psychiatric medications alongside psilocybin) and were treated under "heterogeneous treatment conditions" [s1], both departures from the standardized single-intervention protocols typical of controlled trials. That gap between trial and real-world effectiveness is itself the useful finding, offering a more grounded expectation for what psilocybin therapy might achieve as it moves beyond the clinical trial setting into wider practice, as is beginning to happen in jurisdictions like Switzerland.

What Switzerland's legal pathway actually allows

Psilocybin is not approved as an antidepressant anywhere, but Switzerland's regulatory framework permits limited medical use for treatment-resistant depression outside of a formal clinical trial — a distinctive legal status that made this real-world data collection possible in the first place [s1]. That framework is not the same as full regulatory approval; it represents a narrower, compassionate-access-style pathway specific to Switzerland's regulatory system.

What this doesn't establish

Nineteen patients is a small sample, and this is a retrospective chart review rather than a prospective study — meaning the data was extracted from existing medical records rather than collected under a predetermined research protocol, which the authors acknowledge introduces its own limitations around consistency and completeness of measurement [s1]. There was no control or comparison group, no blinding, and treatment conditions varied across patients (different dosing session counts, one to four; different concomitant medications) [s1] — all factors that make it impossible to isolate psilocybin's specific effect from the broader context of care each patient received. The study's authors are explicit about all of these limitations directly in their own summary [s1].

Why this study still matters despite its limits

As psilocybin therapy programs expand into legal but non-trial settings — Switzerland's framework, Oregon and Colorado's psilocybin service programs in the US, and similar developments elsewhere — real-world outcome data like this becomes increasingly relevant for setting realistic expectations, both for patients considering treatment and for the clinicians and regulators shaping how these programs operate. This study is explicitly framed by its authors as providing "some of the first evidence on psilocybin outside controlled trials" [s1], a genuinely novel contribution regardless of its small scale.

What to watch

Whether larger real-world cohorts, potentially pooling across Switzerland's psilocybin program or similar frameworks elsewhere, confirm this real-world-versus-trial effectiveness gap, and whether specific factors — dosing session count, concomitant medications — are eventually identified as predictors of real-world response. Psilocybin is not approved for depression in most jurisdictions; this article describes real-world clinical outcome data from a specific legal framework and is not medical advice.

Sources

1. Real-World Psilocybin Therapy for Treatment-Resistant Depression: A Retrospective Observational Study — The Lancet Regional Health – Europe, 1 June 2026